OPSMILL
28.5.2024 12:01:28 CEST | Business Wire | Press release
OpsMill, a pioneer in infrastructure and network automation, today announced the beta release of its open source Infrahub platform. Infrahub unifies previously disparate automation capabilities into a single platform, enabling IT teams to transform all their data center, cloud, network, and security infrastructure operations with scalable and consumable automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528726475/en/
Infrahub brings the worlds of infrastructure-as-code and infrastructure management together in a single platform (Graphic: Business Wire)
“I’ve spent years building automation systems for infrastructure and network management across a variety of organizations. At every stop, I encountered the same challenges: Managing network and cloud infrastructure required the use of a confusing, cumbersome, costly mix of solutions. These tools were always hampered by serious technical limitations, such as inflexible data models,” said Damien Garros, CEO and co-Founder, OpsMill. “With the release of Infrahub’s open beta, we’ve drawn on years of experience to solve those challenges. This is the first platform that unites the GitOps Infrastructure-as-Code approach with an extensible structured data model. By combining these two approaches, Infrahub frees infrastructure and automation teams from having to integrate and maintain a fragile set of tools. Instead, they can focus on driving innovation through better automation.”
Infrastructure automation has suffered from an unhelpful divide between GitOps and traditional infrastructure management approaches that prevents teams from gaining the critical advantages and best practices of both approaches. GitOps, an automation approach used by many software development teams, offers version control and continuous integration (CI) validation, which are critical for maintaining an accurate data model while scaling automation use. However, GitOps doesn’t offer a structured data model that most easily represents IT infrastructure components and their many inter-linkages. Traditional infrastructure management approaches offer infrastructure-friendly structured databases, but don’t include version control or CI, and are constrained by fixed data models that limit their flexibility.
Infrahub unifies the best of both worlds in a single platform, including the following key capabilities:
- Extensible Graph Database: Infrahub overcomes the limitations of source-of-truth databases that come with fixed schemas. It is built on an extensible, knowledge-graph database that is ideal for representing and querying the many interrelationships between infrastructure components. Infrahub’s flexible data model means that it can scale across data centers, clouds, networks, and security infrastructure and use cases.
- Version Control: Infrahub makes versioning possible for your entire data model and all the data populated into that model. This means that multiple members of your team can, in parallel, create a branch of the entire infrastructure database, update an infrastructure component in the database in order to generate configuration files for a network change, then merge the updates back into the database. Native versioning of a centralized and extensible infrastructure database is a key innovation of Infrahub.
- Artifact Rendering: Infrahub doesn’t leave you alone in managing the generation of artifacts such as configuration files or reporting data files. It includes native artifact rendering as a native platform capability.
- Continuous Integration (CI): Infrahub has built in the process for performing CI validations to ensure quality control over configuration and data changes.
“As someone who has engineered large backbone networks and helped build a company that relied on extensive network and cloud infrastructure, I’ve seen firsthand how much organizations struggle with scalable and maintainable automation,” said Raphael Maunier, COO and co-Founder, OpsMill. “Infrastructure teams often need their own dev teams just to gather data and build infrastructure, leading to high maintenance costs and slowed innovation. OpsMill was founded to change this. Infrahub provides all the key elements for scalable infrastructure and network automation success, allowing teams to focus on innovation instead of maintaining custom software.”
The open beta version of Infrahub is available now. Visit GitHub to get started today.
About OpsMill
OpsMill is the infrastructure automation platform company, bringing the best practices and features of the industry’s leading automation approaches together in a single, scalable, and extensible platform so that infrastructure, cloud, network, and security teams can focus on innovation rather than integrating toolsets. Infrahub by OpsMill is the industry’s leading open-source integrated infrastructure automation platform. OpsMill is backed by Serena Capital, Partech, OVNI Capital, Kima Ventures and Better Angle. For more information, visit OpsMill.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528726475/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
